Closely held Intarcia Therapeutics said its implantable drug-delivery pump proved superior to Merck’s top-selling drug Januvia in helping diabetes patients control blood sugar in a head-to-head clinical trial.
from WSJ.com: US Business http://ift.tt/1E4bKsm
via IFTTT
No comments:
Post a Comment